T raumaTic brain injury is a common cause of mortality and morbidity in the US, particularly among the young. 39 The most prevalent and debilitating features in survivors of TBI are cognitive deficits and motor dysfunctions. 10 To date, there is no effective treatment identified to promote functional recovery after TBI except for routine medical intervention and care. 29, 31 Erythropoietin and the EPO receptor, essential for erythropoiesis, are also expressed in the neurons, astrocytes, and cerebral endothelial cells. Erythropoietin shows neuroprotection in animal models of stroke, Object. This efficacy study was designed to investigate traumatic brain injury (TBI) in rats treated with delayed erythropoietin (EPO) administered in a single dose compared with a triple dose.
T raumaTic brain injury is a common cause of mortality and morbidity in the US, particularly among the young. 39 The most prevalent and debilitating features in survivors of TBI are cognitive deficits and motor dysfunctions. 10 To date, there is no effective treatment identified to promote functional recovery after TBI except for routine medical intervention and care. 29, 31 Erythropoietin and the EPO receptor, essential for erythropoiesis, are also expressed in the neurons, astrocytes, and cerebral endothelial cells. Erythropoietin shows neuroprotection in animal models of stroke, 14, 40 spinal cord injury, 4, 15, 17 concussive brain injury, 3 kainateinduced seizure activity, 3 and autoimmune encephalomyelitis. 5, 32 Most studies for TBI have investigated either a single dose or multiple doses of EPO pretreatment (prior to injury) or treatment within 6 hours of injury. 3, 8, 18, 30 Several lines of evidence have demonstrated that single-dose EPO administered within 6 hours of TBI reduced lesion volume. 8, 16, 18 Our recent work further demonstrated that delayed EPO treatment (24 hours postinjury) provided long-term benefits in rats after TBI 21, 26 and after stroke. 40 Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose
Although delayed EPO treatment enhances angiogenesis in rats after stroke, 40 it is unclear whether delayed therapy induces angiogenesis after TBI. Delayed EPO therapy improves long-term sensorimotor functional recovery after stroke 40 and spatial learning performance after TBI. 26 However, it is not known whether delayed administration of EPO improves long-term sensorimotor functional recovery after TBI. In addition, there is no study comparing the efficacy of multiple doses of EPO with a single dose for treatment of TBI. Accordingly, using a CCI TBI rat model, we tested the hypotheses and demonstrated the following: 1) delayed administration of EPO reduces brain injury, increases cell proliferation, neurogenesis, and angiogenesis, and improves long-term sensorimotor function and spatial learning recovery; and 2) 3 doses of EPO is more efficacious than a single dose for treatment of TBI in rats.
Methods
All experimental procedures were approved by the Institutional Animal Care and Use Committee of Henry Ford Health System.
Traumatic Brain Injury Model
A CCI model of TBI in the rat was used in the present study. 12, 25 Young adult male Wistar rats (300-400 g) were anesthetized intraperitoneally with chloral hydrate (350 mg/kg body weight). Rectal temperature was maintained at 37°C using a feedback-regulated water-heating pad. A CCI device was used to induce injury. Rats were placed in a stereotactic frame. Two 10-mm-diameter craniotomies were made adjacent to the central suture, midway between lambda and bregma. The second craniotomy allowed for lateral movement of cortical tissue. The dura mater was kept intact over the cortex. Injury was delivered by impacting the left cortex (ipsilateral cortex) with a pneumatic piston containing a 6-mm-diameter tip at a rate of 4 m/second and 2.5 mm of compression. Velocity was measured with a linear velocity displacement transducer.
Experimental Groups and Treatment
Young adult male Wistar rats were randomly divided into 4 groups: 1) sham group (6 animals); 2) TBI/saline group (6 animals); 3) TBI plus 1 dose of EPO (TBI/ EPO×1) group (6 animals); and 4) TBI plus 3 doses of EPO (TBI/EPO×3) group (7 animals). Traumatic brain injury was induced by CCI over the left parietal cortex. Sham rats underwent surgery without injury. We administered EPO at a dose of 5000 U/kg body weight (Epoetin alpha, Amgen) intraperitoneally on Day 1 (EPO×1 group) or on Days 1, 2, and 3 (EPO×3 group) after TBI. The EPO dose was selected based on previous studies. 21, 45 Animals in the saline-treated group received an equal volume of saline on Days 1, 2 and 3 after surgery. For labeling proliferating cells, BrdU (100 mg/kg, Sigma) was injected intraperitoneally into rats daily for 10 days, starting 1 day after TBI. All rats were killed 35 days after TBI or surgery.
Hematocrit Level
To determine the effects of EPO on HCT, a blood sample (50 μl) was collected via the tail vein before injury, on Day 4 , and weekly after TBI or sham treatment up to 5 weeks. Hematocrit was measured in micro-HCT capillary tubes (Fisher Scientific) using standard procedures (Readacrit Centrifuge). 42 
Evaluation of Neurological Outcome
Investigators blinded to the treatment status performed all functional tests.
Morris Water Maze Test
To detect spatial learning impairments, a recent version of the MWM test was used. 9 The procedure was modified from previous versions 11, 27, 28, 37 and has been found to be useful for chronic spatial memory assessment in rats and mice with brain injury. 9, 21 All animals were tested during the last 5 days (that is, from 31-35 days after TBI or surgery) before planned death. Data collection was automated by the HVS Image 2020 Plus Tracking System (US HVS Image). For data collection, a blue pool (1.8 m in diameter) was subdivided into 4 equal quadrants formed by imaging lines. At the start of a trial, the rat was placed at 1 of 4 fixed starting points, randomly facing toward a wall (designated north, south, east, and west) and allowed to swim for 90 seconds or until it found the platform. If the animal found the platform, it was allowed to remain on it for 10 seconds. If the animal failed to find the platform within 90 seconds, it was placed on the platform for 10 seconds. Throughout the test period the platform was located in the northeast quadrant 2 cm below water in a randomly changing position, including locations against the wall, toward the middle of the pool, or off-center but always within the target quadrant. If the animal was unable to find the platform within 90 seconds, the trial was terminated and a maximum score of 90 seconds was assigned. If the animal reached the platform within 90 seconds, the percentage of time traveled within the northeast (correct) quadrant was calculated relative to the total amount of time spent swimming before reaching the platform and was used for statistical analysis. The advantage of this version of the water maze is that each trial takes on the key characteristics of a probe trial because the platform is not in a fixed location within the target quadrant. 33 
Foot-Fault Test
To evaluate sensorimotor function, the foot-fault test was carried out before TBI and on Days 1, 4, 7, 14, 21, 28, and 35 after TBI or surgery. The rats were allowed to walk on a grid. 43 With each weight-bearing step, a paw might fall or slip between the wires, and, if this occurred, it was recorded as a foot fault.
1,2 A total of 50 steps were recorded for each right forelimb and hindlimb.
Modified Neurological Severity Score
Neurological functional measurement was performed using the mNSS score. 6 The test was conducted on all rats before injury and on Days 1, 4, 7, 14, 21, 28, and 35 after TBI. The mNSS score is a composite of the motor (muscle status, abnormal movement), sensory (visual, tactile, and proprioceptive), and reflex tests and has been used in previous studies. 22 In this TBI model, injury in the left hemispheric cortex of rats causes sensory and motor functional deficiency with elevated scores on motor, sensory, and beam-balance tests in the early phase after injury (Day 1 postinjury). Absent reflexes and abnormal movements can be measured in rats with severe injury. Slow recovery in asymmetry deficiency, as reflected by beam balance test results has been reported in unilateral brain injuries including TBI 22 and ischemia. 6 This test is suitable for evaluating long-term neurological function after unilateral brain injury.
Tissue Preparation and Measurement of Lesion Volume
On Day 35 after TBI, rats were anesthetized intra peritoneally with chloral hydrate and were perfused trans cardially, first with saline solution and then with 4% paraformaldehyde in 0.1 M PBS (pH 7.4). Their brains were removed and postfixed in 4% paraformaldehyde for 2 days at room temperature. The brain tissue was cut into 7 equally spaced 1-mm coronal blocks and processed for paraffin sectioning. A series of adjacent 6-μm-thick sections were cut from each block in the coronal plane and stained with H & E. For lesion volume measurement, the 7 brain sections were traced by a MCID (Imaging Research), as previously described. 7 The indirect lesion area was calculated (that is, the intact area of the ipsilateral hemisphere is subtracted from the area of the contralateral hemisphere), 38 and the lesion volume presented as a volume percentage of the lesion compared with the contralateral hemisphere. Hematoxylin and eosin sections from Blocks E and F containing hippocampus were used to acquire images of the dentate gyrus and CA3 regions at a magnification of 20. To evaluate the cell loss after TBI, we counted the cell number per millimeter in the dentate gyrus and CA3 regions.
Immunohistochemistry
To examine the effect of EPO on cell proliferation and angiogenesis, coronal sections were histochemically stained with mouse anti-BrdU 21 and rabbit anti-human vWF, 21 respectively. For BrdU detection, paraffin-embedded coronal sections (6 μm) were deparaffinized and rehydrated. Antigen retrieval was performed by boiling sections in 10-mM citrate buffer (pH 6.0) for 10 minutes (Chen et al., 2001 6 ). After washing with PBS, sections were incubated with 0.3% H 2 O 2 in PBS for 10 minutes, blocked with 1% BSA containing 0.3% Triton-X 100 for 1 hour at room temperature, and incubated with mouse anti-BrdU (1:200 dilution, Dako) at 4°C overnight. After washing, sections were incubated with biotinylated anti-mouse antibody (1:200 dilution, Vector Labs, Inc.) at room temperature for 30 minutes. After washing, sections were incubated with an avidin-biotin-peroxidase system (ABC Kit, Vector Labs, Inc.). Diaminobenzidine (Sigma) was then used as a sensitive chromogen for light microscopy. Sections were counterstained with hematoxylin.
To identify vascular structure, brain sections were deparaffinized and then incubated with 0.4% Pepsin solution at 37°C for 1 hour. After washing, the sections were blocked with 1% BSA at room temperature for 1 hour, and then incubated with rabbit anti-human vWF (1:200 dilution, DakoCytomation) at 4°C overnight. After washing, sections were incubated with biotinylated anti-rabbit antibody (1:200 dilution, Vector Labs, Inc.) at room temperature for 30 minutes. The subsequent procedures were the same as for BrdU staining.
We examined BrdU-positive cells and vWF-stained vascular structures in the dentate gyrus, CA3, and the cortex of ipsilateral hemispheres at a magnification of 20 and counted. The cells with BrdU (brown stained) that clearly localized to the nucleus (hematoxylin stained) were counted as BrdU-positive cells.
Immunofluorescent Staining
Newly generated neurons were identified by double labeling for BrdU and NeuN. After rehydration, tissue sections were boiled in 10 mM citric acid buffer (pH 6) for 10 minutes. After washing with PBS, sections were incubated in 2.4 N HCl at 37°C for 20 minutes. Sections were incubated with 1% BSA containing 0.3% Triton-X-100 in PBS. Sections were then incubated with mouse anti-NeuN antibody (1:200 dilution, Chemicon) at 4°C overnight. Fluorescein isothiocyanate-conjugated antimouse antibody (1:400 dilution, Jackson ImmunoResearch) was added to sections at room temperature for 2 hours. Sections were then incubated with rat anti-BrdU antibody (1:200 dilution, Dako) at 4°C overnight. Sections were next incubated with Cy3-conjugated anti-rat antibody (1:400 dilution, Jackson ImmunoResearch) at room temperature for 2 hours. Each of the steps was followed by three 5-minute rinses in PBS. Tissue sections were mounted with Vectashield mounting medium (Vector Labs, Inc.). Images were collected with fluorescent microscopy. The NeuN/BrdU-colabeled cells in the dentate gyrus and the cortex were counted at a magnification of 40.
Cell Counting and Quantitation
Cell counts were performed by observers blinded to the individual treatment status of the rats. Five sections with 50-μm intervals from the dorsal dentate gyrus were analyzed with a microscope (Nikon i80) at a magnification of 400 with the MCID system. 21 All counting was performed on a computer monitor to improve visualization and in 1 focal plane to avoid oversampling. 43 To evaluate whether intraperitoneally administered EPO reduces neuronal damage after TBI, the number of cells was counted in the dentate gyrus and CA3 region using the MCID system. Although H & E staining is not neuron specific, the morphological characteristics of neuronal cells in the dentate gyrus and CA3 region aid in counting them. Counts were averaged and normalized by measuring the linear distance (in mm) of the dentate gyrus and CA3 for each section. Although it is just an estimate of the cell number, this method permits a meaningful comparison of differences between groups. For cell prolifera-tion, the total number of BrdU-positive cells was counted in the lesion boundary zone and the dentate gyrus, using the MCID system. The cells with BrdU (brown stained) that clearly localized to the nucleus (hematoxylin stained) were counted as BrdU-positive cells. The number of BrdU-positive cells was expressed in cells/mm 2 in the lesion boundary zone or in cells/mm in the hippocampus. For analysis of neurogenesis, additional sections used in the aforementioned studies were used to evaluate neurogenesis in the dentate gyrus and the cortex by calculating the density of BrdU-labeled cells and BrdU/NeuN-colabeled cells. 24 We mainly focused on the ipsilateral dentate gyrus and its subregions, including the subgranular zone, granular cell layer, and the molecular layer. The number of BrdU-positive cells (red stained) and NeuN/ BrdU-colabeled cells (yellow after merge) were counted in the dentate gyrus and the lesion boundary zone. The percentage of NeuN/BrdU-colabeled cells over the total number of BrdU-positive cells in the corresponding regions (dentate gyrus or cortex) was estimated and used as a parameter to evaluate neurogenesis. 42 
Statistical Analysis
All data are presented as the means ± SD. Data were analyzed by ANOVA for repeated measurements of HCT and functional tests (spatial performance and sensorimotor function). For lesion volume, cell counting, cell proliferation, and vWF-stained vascular density, a 1-way ANOVA followed by post hoc Student-Newman-Keuls tests were used to compare the difference among the EPO-treated, saline-treated, and sham groups. Statistical significance was set at p < 0.05.
Results

Hematocrit
The baseline of HCT was similar in all animals before injury or sham surgery (Fig. 1) . Compared with saline treatment, EPO treatment significantly increased HCT for up to 1 week (EPO×1 group, p = 0.003) and 2 weeks (EPO×3 group, p = 0.026); HCT returned to normal thereafter. Hematocrit was significantly higher at 2 weeks in the EPO×3 group than the EPO×1 group (p = 0.031).
Lesion Volume
Rats were killed 35 days after TBI for histological measurements. Treatment with EPO did not affect the lesion volume after TBI. The lesion volume was 16.9 ± 1.4, 15.7 ± 0.5, and 16.0 ± 1.5% for TBI rats treated with saline, EPO×1, and EPO×3, respectively.
Spatial Learning Test
The water maze protocol was used to detect spatial learning deficits. To analyze day-by-day differences in the MWM, a repeated-measures ANOVA was performed and followed by Student-Newman-Keuls tests for multiple comparisons. As shown in Fig. 2 
Foot-Fault Test
The incidence of forelimb foot faults during baseline (preoperative) testing was ~ 4-5% (Fig. 3) . Sham surgery alone mildly increased the frequency of foot faults on postoperative Days 1 and 4. Traumatic brain injury significantly increased the occurrence of right forelimb foot faults contralateral to the side of TBI on 1-35 days after injury compared with the preinjury baseline. Treatment with 3 doses of EPO significantly reduced the number of contralateral forelimb foot faults on Days 7-28 after TBI compared with saline treatment (p = 0.015, 0.011, 0.024, and 0.035 for Days 7, 14, 21, and 28, respectively), while a single dose (EPO×1 group) showed benefits on Days 7 (p = 0.01) and 14 (p = 0.014).
Similar results were found for the contralateral hindlimb (Fig. 4) . Compared with preinjury baseline, TBI significantly increased the incidence of contralateral hindlimb foot faults on of contralateral hindlimb foot faults on Days 7-28 after TBI compared with saline treatment (p = 0.031, 0.026, 0.020, and 0.042 for Days 7, 14, 21, and 28, respectively), whereas a single dose (EPO×1 group) showed benefits on Days 7-21 (p = 0.033, 0.028, and 0.044 for Days 7, 14, and 21, respectively). Figure 5 shows that there was no significant difference in the mNSS score among the saline, EPO×1, and EPO×3 groups on Day 4 after TBI. However, significantly improved scores were seen on Days 7-35 after TBI in the EPO×3 group compared with the saline group (p = 0.022, 0.030, 0.033, 0.037, and 0.039 for Days 7, 14, 21, 28, and 35, respectively). A single dose of EPO therapy had a tendency to reduce the mNSS score on Days 7-21 without reaching a significance, but it significantly reduced the mNSS score on Days 28 (p = 0.033) and 35 (p = 0.045) compared with saline therapy. Treatment with 3 doses showed significantly improved benefits on Days 7 (p = 0.014) and 14 (p = 0.044) compared with a single-dose therapy.
Neurological Severity Score
Cell Loss in the CA3 and Dentate Gyrus
When examined on Day 35 after TBI (Fig. 6) , the neuron counts in the ipsilateral CA3 (p = 0.003) and dentate gyrus (p = 0.010) had significantly decreased after TBI (Fig. 6b and f) compared with sham controls (Fig. 6a and  e) . Compared with saline controls, a single dose of EPO treatment significantly increased the neuron counts in the CA3 (p = 0.035) but not in the dentate gyrus. Three doses of EPO treatment produced significantly higher neuron counts than a single dose group in the CA3 (compare Fig.  6d and 6c ; p = 0.044) and dentate gyrus (compare Fig. 6h  and 6g ; p = 0.035).
Angiogenesis
Von Willebrand factor staining has been used to identify vascular structures in the brain after TBI. 23 Traumatic brain injury alone significantly increased the density of vessels in the cortex (p = 0.018), CA3 (p = 0.035), and dentate gyrus (p = 0.044) of the ipsilateral hemisphere compared with sham controls (Fig. 7) . Treatment with EPO significantly increased the vascular density in the cortex (p = 0.047 for EPO×1; p = 0.039 for EPO×3), CA3 (p = 0.038 for EPO×1; p = 0.044 for EPO×3) and dentate gyrus (p = 0.042 for EPO×1; p = 0.022 for EPO×3) compared with saline treatment (Fig. 7) . There was no significant difference in the vascular density between the EPO×1 and EPO×3 groups.
Cell Proliferation
An analog of thymidine, BrdU is commonly used to detect proliferating cells in living tissues. It can be incorporated into the newly synthesized DNA of replicating cells during the S phase of the cell cycle, substituting for thymidine during DNA replication. The number of BrdUpositive cells found in the ipsilateral cortex (p = 0.008) and dentate gyrus (p = 0.006) areas was significantly increased 35 days after TBI compared with sham controls (Fig. 8) . However, EPO treatment further increased the number of BrdU-positive cells in the cortex (p = 0.015 for EPO×1; p = 0.012 for EPO×3) and dentate gyrus (p = 0.010 for EPO×1; p = 0.018 for EPO×3) after TBI com- pared with saline controls (Fig. 8) . There was no significant difference in the number of BrdU-positive cells in these regions between the EPO×1 and EPO×3 groups.
Neurogenesis
Newly generated neurons were identified by double labeling for BrdU (proliferating marker) and NeuN (mature neuronal marker). The number of NeuN/BrdU-colabeled cells (newborn neurons) was significantly higher in the injured cortex (p = 0.014) and dentate gyrus (p = 0.010) after TBI compared with sham controls (compare Fig. 9b with 9a and Fig. 9f with 9e) . Treatment with EPO significantly increased the number of newborn neurons in the injured cortex (p = 0.027 for EPO×1; p = 0.022 for EPO×3) and dentate gyrus (p = 0.019 for EPO×1;p = 0.021 for EPO×3) (Fig. 9c, d , g, and h) compared with saline controls. The number of newborn neurons in the injured cortex (p = 0.031) and dentate gyrus (p = 0.041) was significantly higher in the EPO×3 group than in the EPO×1 group (compare Fig. 9c with 9d and Fig. 9g with  9h) . Treatment with EPO significantly increased the percentage of NeuN/BrdU-colabeled cells in the injured cortex (p = 0.047 for EPO×1; p = 0.034 for EPO×3) (Fig.  9p) compared with saline controls. The percentage of newborn neurons in the injured cortex was significantly higher in the EPO×3 group than in the EPO×1 group (p = 0.044). However, there was no significant difference in the percentage of newborn neurons in the dentate gyrus among sham, saline-treated, and EPO-treated groups.
Discussion
The main findings of the present study are as follows: 1) delayed EPO treatment (24 hours postinjury) after TBI provides long-term behavioral benefits, as reflected in improvements in sensorimotor functional recovery and spatial learning, as evaluated by MWM test, foot-fault test, and the mNSS score; 2) the improvements in spatial learning and sensorimotor function may derive from the effect of EPO on reducing hippocampal cell loss and increasing angiogenesis and neurogenesis; and 3) although a single EPO dose showed substantial benefits after TBI, the 3-dose paradigm provided a better outcome in terms of reducing hippocampal cell loss, enhancing neurogenesis, and improving spatial learning and sensorimotor functional recovery.
There are several major differences between the present work and earlier studies. In our previous study we demonstrated that delayed EPO treatment significantly increased neurogenesis and improved spatial memory when the EPO was given daily for 14 days starting 24 hours after TBI in rats. Sensorimotor function and spatial learning were not examined in that short-term survival (14-day) study. 21 In the present study of 35-day survival after CCI in rats we found that delayed EPO treatment not only significantly improved the spatial learning function (acquisition) on Days 33-35 after CCI but also promoted sensorimotor functional recovery (reduced foot faults and improved mNSS score).
Erythropoietin given subcutaneously within 6 hours of TBI has been shown to reduce lesion volume and cell loss in the CA1 and CA3 region of the hippocampus (functional outcome not measured in that study). 8 It should be noted that intraperitoneal injection yielded a faster and greater peak concentration of plasma EPO than subcutaneous injection. 34 This may partially explain why the present delayed (24-hour) EPO treatment (intraperitoneal) provided substantial benefits while the 12-hour EPO treatment (subcutaneous) did not show significant neuroprotection (without data on 24-hour injection). 8 Many of the treatments including EPO in experimental TBI were given immediately or within 6 hours after TBI. 8, 16, 18, 20 The translation of early TBI therapies from the laboratory to the clinic (Phase III) has not been successful. 29 Our previous study has demonstrated that apoptotic cells in the ipsilateral cortex and hippocampus were observed as early as 2 hours after the impact, peaked at 2 days, and gradually tapered off afterward. 19 Our present findings demonstrated that delayed EPO therapy reduced hippocampal cell loss, enhanced angiogenesis and neurogenesis, and improved functional outcomes after TBI, further indicating that the therapeutic time window may not be limited to early hours and can be extended to later time periods.
Our previous studies have shown that early (6-hour) EPO therapy did not affect angiogenesis in mice after TBI 41 and that delayed (24-hour) EPO treatment significantly increased angiogenesis after stroke in rats. 40 Our present study demonstrated for the first time that delayed EPO treatment increased angiogenesis in the ipsilateral hippocampus and cortex in rats after TBI. Under physiological conditions, neurogenesis in the subgranular zone of the dentate gyrus and SVZ takes place within an an- giogenic microenvironment. 47 In vivo, neurogenesis and angiogenesis are highly interdependent and work together to promote brain remodeling and subsequent improvement of neurological functional after brain injury. 47 Our present data support the coupling of angiogenesis and neurogenesis, which is shown by the increased number of NeuN/ BrdU-positive cells in the injured cortex and hippocampus where angiogenesis is also enhanced after TBI. The present study demonstrated that EPO treatment further increased angiogenesis and neurogenesis. In the present study, EPO significantly increased the total number and percentage of newborn neurons found in the injured cortex, suggesting the EPO may induce SVZ-derived neurogenesis-that is, migration of newborn blasts from the SVZ into the injured cortex where some of SVZ-derived newborn blasts differentiate into mature neurons. 13, 36, 44, 46 Although EPO therapy significantly increased the total number of newborn neurons in the dentate gyrus, it did not change the percentage (~ 80% in this study) of newborn neurons, indicating that most of the BrdU-positive cells in the dentate gyrus differentiate into granule neurons and that cell-lineage commitment patterns do not change in the dentate gyrus after TBI and EPO therapy. This finding is in agreement with the report that the majority of BrdU-positive cells in the dentate gyrus become granule neurons after TBI and these neurons exhibit extensive anatomical integration into the CA3 region at the time cognitive recovery is observed. 35 Our present data suggest that newborn neurons may participate in brain repair and functional recovery.
To our knowledge, the present study was the first time to compare the efficacy of a single dose with that of triple doses of delayed EPO treatment for TBI. Traumatic brain injury upregulated the expression of EPO and EPO receptor in rats. 20 However, EPO upregulation is transient (3 days) while increased EPO receptor expression lasts at least 7 days. 20 These findings suggest that transiently increased endogenous EPO level does not match prolonged increased EPO receptor and therefore may not provide enough neuroprotection. In addition, prolonged EPO receptor upregulation provides a platform for exogenous EPO treatment and suggests multiple doses may be required. In the present study, a single dose of delayed EPO therapy had substantial benefits (that is, significantly reducing hippocampal cell loss, increasing angiogenesis and neurogenesis, and improving functional recovery), while 3 doses of EPO provided better outcomes. 
Conclusions
Delayed (24-hour) EPO therapy for TBI significantly reduced hippocampal cell loss, enhanced angiogenesis and neurogenesis, and improved sensorimotor function and spatial learning recovery, suggesting that delayed EPO treatment is both neuroprotective and neurorestorative. Our data also demonstrated that a multiple dosing protocol of EPO provided better efficacy than a single EPO dose for treatment initiated at 24 hours after TBI.
